Friedreich's Ataxia Clinical Trial
Official title:
A Phase III Open-Label, Single Group Extension Study of the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
This study is meant to assess the safety and tolerability of idebenone in patients with Friedreich's Ataxia over a 12 months period.
The study involves 6 clinic visits. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02660112 -
(+) Epicatechin to Treat Friedreich's Ataxia
|
Phase 2 | |
Recruiting |
NCT02497534 -
Biomarkers in Friedreich's Ataxia
|
||
Completed |
NCT04102501 -
A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT01962363 -
EPI-743 in Friedreich's Ataxia Point Mutations
|
Phase 2 | |
Completed |
NCT02179333 -
Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)
|
||
Completed |
NCT01016366 -
Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia
|
Phase 2 | |
Recruiting |
NCT02069509 -
Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)
|
||
Terminated |
NCT00803868 -
Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia
|
Phase 2/Phase 3 | |
Completed |
NCT02797080 -
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT02415127 -
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT00897221 -
A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT02840669 -
A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)
|
N/A | |
Recruiting |
NCT02316314 -
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
|
||
Completed |
NCT00631202 -
Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT01728064 -
Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT02593773 -
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
|
Phase 3 | |
Completed |
NCT01035671 -
Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT00811681 -
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept
|
Phase 3 | |
Completed |
NCT00537680 -
Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia
|
Phase 3 | |
Completed |
NCT02445794 -
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
|
Phase 1/Phase 2 |